$0.64
7.30% yesterday
Nasdaq, Apr 03, 10:12 pm CET
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Ocugen Inc Stock price

$0.64
+0.03 5.55% 1M
-0.31 32.59% 6M
-0.17 20.66% YTD
-0.87 57.56% 1Y
-2.81 81.49% 3Y
+0.36 128.11% 5Y
-593.36 99.89% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.05 7.30%
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Key metrics

Market capitalization $186.51m
Enterprise Value $160.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 39.53
P/S ratio (TTM) P/S ratio 45.94
P/B ratio (TTM) P/B ratio 6.28
Revenue growth (TTM) Revenue growth 187.79%
Revenue (TTM) Revenue $4.06m
EBIT (operating result TTM) EBIT $-54.76m
Free Cash Flow (TTM) Free Cash Flow $-45.53m
Cash position $58.51m
EPS (TTM) EPS $-0.18
P/E forward negative
Short interest 23.51%
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

Buy
100%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4.06 4.06
188% 188%
100%
- Direct Costs 1.97 1.97
103% 103%
49%
2.09 2.09
375% 375%
51%
- Selling and Administrative Expenses 23 23
25% 25%
560%
- Research and Development Expense 32 32
15% 15%
791%
-53 -53
22% 22%
-1,300%
- Depreciation and Amortization 1.97 1.97
103% 103%
49%
EBIT (Operating Income) EBIT -55 -55
20% 20%
-1,349%
Net Profit -54 -54
16% 16%
-1,331%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
GlobeNewsWire
17 days ago
MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Ph...
Neutral
Seeking Alpha
29 days ago
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. ...
Neutral
GlobeNewsWire
30 days ago
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three years Completed dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2.
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website www.ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today